Cargando…
Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
The survival rate of patients with breast cancer has been improved by immune checkpoint blockade therapies, and the efficacy of their combinations with epigenetic modulators has shown promising results in preclinical studies. In this prospective study, we propose an ordinary differential equation (O...
Autores principales: | Wang, Hanwen, Sové, Richard J., Jafarnejad, Mohammad, Rahmeh, Sondra, Jaffee, Elizabeth M., Stearns, Vered, Torres, Evanthia T. Roussos, Connolly, Roisin M., Popel, Aleksander S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051945/ https://www.ncbi.nlm.nih.gov/pubmed/32158754 http://dx.doi.org/10.3389/fbioe.2020.00141 |
Ejemplares similares
-
QSP‐IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno‐Oncology Applications
por: Sové, Richard J., et al.
Publicado: (2020) -
A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor
por: Ma, Huilin, et al.
Publicado: (2020) -
Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide
por: Mirando, Adam C., et al.
Publicado: (2020) -
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Wang, Hanwen, et al.
Publicado: (2021) -
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
por: Sové, Richard J, et al.
Publicado: (2022)